These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33639215)

  • 1. MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.
    Laudermilch E; Chandran K
    J Mol Biol; 2021 Apr; 433(9):166896. PubMed ID: 33639215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Method for Generating Point Mutations in the Vaccinia Virus Genome Using CRISPR/Cas9.
    Boutin L; Mosca E; Iseni F
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid poxvirus engineering using CRISPR/Cas9 as a selection tool.
    Gowripalan A; Smith S; Stefanovic T; Tscharke DC
    Commun Biol; 2020 Nov; 3(1):643. PubMed ID: 33144673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of Vaccinia Virus Recombinants Using CRISPR/Cas9.
    Gowripalan A; Smith SA; Tscharke DC
    Bio Protoc; 2021 Dec; 11(24):e4270. PubMed ID: 35087929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinia Virus Genome Editing Using CRISPR.
    Di Gioia C; Yuan M; Wang Y
    Methods Mol Biol; 2019; 2023():109-117. PubMed ID: 31240673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput engineering of cytoplasmic- and nuclear-replicating large dsDNA viruses by CRISPR/Cas9.
    López-Muñoz AD; Rastrojo A; Martín R; Alcami A
    J Gen Virol; 2022 Oct; 103(10):. PubMed ID: 36260063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.
    Okoli A; Okeke MI; Tryland M; Moens U
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29361752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.
    Yuan M; Zhang W; Wang J; Al Yaghchi C; Ahmed J; Chard L; Lemoine NR; Wang Y
    J Virol; 2015 May; 89(9):5176-9. PubMed ID: 25741005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus.
    Senkevich TG; Zhivkoplias EK; Weisberg AS; Moss B
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32669330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome scale patterns of recombination between coinfecting vaccinia viruses.
    Qin L; Evans DH
    J Virol; 2014 May; 88(10):5277-86. PubMed ID: 24574414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient method for generating poxvirus recombinants in the absence of selection.
    Rice AD; Gray SA; Li Y; Damon I; Moyer RW
    Viruses; 2011 Mar; 3(3):217-32. PubMed ID: 21494427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts.
    Pfleiderer M; Falkner FG; Dorner F
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():2957-62. PubMed ID: 8847500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants.
    Liu R; Moss B
    J Virol; 2016 Sep; 90(17):7864-79. PubMed ID: 27334583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol.
    Luteijn RD; Drexler I; Smith GL; Lebbink RJ; Wiertz EJHJ
    J Gen Virol; 2018 Jun; 99(6):790-804. PubMed ID: 29676720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker-free genome editing in Ustilago trichophora with the CRISPR-Cas9 technology.
    Huck S; Bock J; Girardello J; Gauert M; Pul Ü
    RNA Biol; 2019 Apr; 16(4):397-403. PubMed ID: 29996713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
    Shen J; Zhou J; Chen GQ; Xiu ZL
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex.
    Cotter CA; Moss B
    J Virol; 2020 May; 94(10):. PubMed ID: 32132239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and isolation of recombinant vaccinia virus using genetic markers.
    Lorenzo MM; Galindo I; Blasco R
    Methods Mol Biol; 2004; 269():15-30. PubMed ID: 15114004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance.
    Hansen SG; Cope TA; Hruby DE
    Biotechniques; 2002 May; 32(5):1178, 1180, 1182-7. PubMed ID: 12019792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.